CCR8 and neoplasm: To improve trafficking and resistance to immunosuppression, CCR8-modified CAR-T cells were transduced for a TGFβ-insensitive receptor (DNRII) and showed consistent tumor regression compared to CCR8-only expressing CAR-T cells (Cadilha et al., 2021).